Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedSep 26, 2025
DataAggregated Company Financials
Companies52
  • 7D0.09%
  • 3M4.2%
  • 1Y-11.8%
  • YTD-16.2%

Over the last 7 days, the Biotech industry has risen 1.3%, driven by gains from BioArctic of 3.5%. In the same time, Bonesupport Holding was down 5.7%. However, the industry is down 10% over the past year. Looking forward, earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Sep 2025SEK 194.4bSEK 36.4bSEK 3.0b31.2x64.2x5.3x
Sun, 24 Aug 2025SEK 196.3bSEK 35.9bSEK 2.7b29.2x73.8x5.5x
Tue, 22 Jul 2025SEK 184.7bSEK 35.9bSEK 2.8b28.2x66.6x5.1x
Thu, 19 Jun 2025SEK 183.3bSEK 35.2bSEK 2.2b28.7x82.2x5.2x
Sat, 17 May 2025SEK 192.5bSEK 33.9bSEK 1.2b34.5x160.3x5.7x
Mon, 14 Apr 2025SEK 169.4bSEK 33.7bSEK 750.2m28.3x225.7x5x
Wed, 12 Mar 2025SEK 187.7bSEK 33.7bSEK 582.0m32.2x322.5x5.6x
Fri, 07 Feb 2025SEK 225.0bSEK 33.7bSEK 289.8m57.7x776.5x6.7x
Sun, 05 Jan 2025SEK 221.9bSEK 33.0b-SEK 4,422,596,365.77162x-50.2x6.7x
Tue, 03 Dec 2024SEK 213.3bSEK 33.0b-SEK 4,445,760,324.15150.4x-48x6.5x
Thu, 31 Oct 2024SEK 222.9bSEK 33.2b-SEK 4,376,431,364.0833.3x-50.9x6.7x
Sat, 28 Sep 2024SEK 217.6bSEK 31.4b-SEK 5,542,929,538.9352.3x-39.3x6.9x
Mon, 26 Aug 2024SEK 209.5bSEK 31.4b-SEK 5,451,247,150.9849.4x-38.4x6.7x
Wed, 24 Jul 2024SEK 213.0bSEK 31.3b-SEK 5,447,085,607.3447.1x-39.1x6.8x
Fri, 21 Jun 2024SEK 193.1bSEK 30.6b-SEK 5,516,922,162.3239x-35x6.3x
Sun, 19 May 2024SEK 191.4bSEK 30.6b-SEK 5,507,222,037.7639.8x-34.7x6.3x
Tue, 16 Apr 2024SEK 179.8bSEK 29.8b-SEK 5,279,682,044.8864.7x-34.1x6x
Thu, 14 Mar 2024SEK 191.0bSEK 29.8b-SEK 5,636,578,997.8158.3x-33.9x6.4x
Sat, 10 Feb 2024SEK 176.3bSEK 29.6b-SEK 5,748,812,027.0660.4x-30.7x6x
Mon, 08 Jan 2024SEK 183.3bSEK 28.7b-SEK 1,198,220,759.0059.9x-153x6.4x
Wed, 06 Dec 2023SEK 174.6bSEK 28.7b-SEK 1,200,948,861.0058.8x-145.4x6.1x
Fri, 03 Nov 2023SEK 159.0bSEK 28.6b-SEK 1,304,911,737.0048.2x-121.8x5.5x
Sun, 01 Oct 2023SEK 161.8bSEK 27.4b-SEK 2,016,197,047.0051.3x-80.2x5.9x
Tue, 29 Aug 2023SEK 154.5bSEK 27.6b-SEK 1,825,740,116.0052.1x-84.6x5.6x
Thu, 27 Jul 2023SEK 155.3bSEK 27.5b-SEK 1,531,665,655.0058.5x-101.4x5.6x
Sat, 24 Jun 2023SEK 165.6bSEK 26.4b-SEK 1,312,079,266.0045.9x-126.2x6.3x
Mon, 22 May 2023SEK 175.1bSEK 26.3b-SEK 1,411,262,591.0046.7x-124.1x6.6x
Wed, 19 Apr 2023SEK 176.4bSEK 25.4b-SEK 2,026,956,582.0041.4x-87x6.9x
Fri, 17 Mar 2023SEK 168.7bSEK 25.4b-SEK 2,016,408,138.0038.4x-83.6x6.6x
Sun, 12 Feb 2023SEK 175.5bSEK 25.3b-SEK 1,664,914,197.0027.5x-105.4x6.9x
Tue, 10 Jan 2023SEK 163.9bSEK 23.8b-SEK 1,842,388,404.0031.5x-88.9x6.9x
Thu, 08 Dec 2022SEK 156.1bSEK 23.8b-SEK 1,772,205,741.0031.6x-88.1x6.6x
Sat, 05 Nov 2022SEK 153.6bSEK 23.9b-SEK 3,207,931,300.0033x-47.9x6.4x
Mon, 03 Oct 2022SEK 152.0bSEK 22.9b-SEK 3,318,606,196.0031.6x-45.8x6.6x
Price to Earnings Ratio

-45.8x


Total Market Cap: SEK 152.0bTotal Earnings: -SEK 3,318,606,196.00Total Revenue: SEK 22.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -34.1x202320242025
Current Industry PE
  • Investors are optimistic on the Swedish Biotechs industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 64.3x which is higher than its 3-year average PE of -34.1x.
  • The 3-year average PS ratio of 6.2x is higher than the industry's current PS ratio of 5.3x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 17% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-1.57%
Healthcare-3.35%
Biotech0.091%
Biotech0.091%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VICO Vicore Pharma HoldingSEK 12.4221.1%
+SEK 506.8m		73.5%PS376.4x
HNSA Hansa BiopharmaSEK 38.8212.0%
+SEK 352.6m		-4.8%PS16.7x
XSPRAY Xspray PharmaSEK 57.008.4%
+SEK 183.7m		12.2%PB4.4x
CRNO B Cereno ScientificSEK 9.165.0%
+SEK 128.1m		30.9%PS46.5x
HAMLET B Hamlet BioPharmaSEK 4.2014.3%
+SEK 93.3m		1.4%PS4191x

Latest News

HNSA
SEK 38.82
Hansa Biopharma
7D
12.0%
1Y
-4.8%
XSPRAY
SEK 57.00
Xspray Pharma
7D
8.4%
1Y
12.2%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
BIOA B
SEK 285.60
BioArctic
7D
-0.9%
1Y
78.4%
SOBI
SEK 272.60
Swedish Orphan Biovitrum
7D
-2.9%
1Y
-16.4%

Altuvoct Adoption And Gamifant Launches Will Unlock European Opportunities

Both the Discount Rate and Net Profit Margin for Swedish Orphan Biovitrum remained essentially stable, supporting the analyst consensus price target, which saw only a marginal decrease from SEK341.18 to SEK340.27. What's in the News Tryngolza (olezarsen) approved in the EU as adjunct therapy for adults with genetically confirmed familial chylomicronemia syndrome (FCS), based on positive Phase 3 data; Sobi holds exclusive commercialization rights outside the U.S., Canada, and China.
VICO
SEK 12.42
Vicore Pharma Holding
7D
21.1%
1Y
73.5%
SYNACT
SEK 21.00
SynAct Pharma
7D
6.9%
1Y
113.2%
BONEX
SEK 288.80
Bonesupport Holding
7D
-6.6%
1Y
-3.7%
BINV
SEK 28.70
BioInvent International
7D
-6.4%
1Y
-40.1%

Investors Don't See Light At End Of BioInvent International AB (publ)'s (STO:BINV) Tunnel And Push Stock Down 26%

Sep 09
Investors Don't See Light At End Of BioInvent International AB (publ)'s (STO:BINV) Tunnel And Push Stock Down 26%
CANTA
SEK 2.59
Cantargia
7D
-8.3%
1Y
-23.1%
SANION
SEK 12.28
Saniona
7D
2.2%
1Y
178.5%
CRNO B
SEK 9.16
Cereno Scientific
7D
5.0%
1Y
30.9%
VITR
SEK 129.10
Vitrolife
7D
-2.1%
1Y
-49.4%

Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business

Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
EGTX
SEK 5.40
Egetis Therapeutics
7D
-5.9%
1Y
22.2%
DVYSR
SEK 141.00
Devyser Diagnostics
7D
-10.2%
1Y
10.6%

Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 25
Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ATORX
SEK 5.04
Alligator Bioscience
7D
24.4%
1Y
-99.6%